Continuing Medical Education (CME)
Cardiovascular Effects of Using GLP-1-Based Therapies for Type 2 Diabetes Mellitus
Credit: 0.25 AMA PRA Category 1 Credit(s)™
Jennifer Green, MD
This 15-minute publication begins with a brief video in which faculty expert Jennifer Green, MD, reviews recent changes in the regulatory requirements for assessing the cardiovascular (CV) safety of new diabetes drugs. The publication then discusses the key CV outcome trials of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and how these results support their use in patients at high risk of CV events.
In collaboration with